



INVESTMENT PLATFORM · DUBAI, UAE

The platform for scaling health & longevity innovation

Technology. Capital. International expansion. We select validated medical solutions and add the rights, capital and execution they need to grow.

POWERED BY



The platform is not theoretical.

Selected platform components already operate across diagnostics, therapy, education and biotechnology.

12M+

tests conducted

Clinics On Cloud · company data

3,500+

diagnostic systems deployed

Clinics On Cloud · company data

30+

countries of operational
presence

Energy Max Group

25%

stake in Energy Max Group

strategic cross-ownership

SELECTED CLIENTS AND PARTNERS OF CLINICS ON CLOUD



The problem is not a lack of innovation, but its fragmentation.

A powerful medical solution cannot become a global asset without an implementation framework.

01

Localization

Technology remains within a single clinic, company or country.

02

Data silos

Diagnosis, treatment and reassessment rarely operate within a single framework.

03

Complex deployment

Each market requires separate regulatory preparation, training and infrastructure.

STRATEGIC GAP

Model42 adds a rights structure, capital and an execution system — transforming innovation into a scalable asset.

Not a clinic. Not a collection of products. A platform.

A UAE-based international platform: an operational portfolio of solutions and an emerging intelligence framework.

OUR VISION

Shaping the future of health and longevity — together.

OUR MISSION

To turn proven medical solutions into repeatable growth models: one framework for diagnostics, medical expertise, data and capital.

OUR PRINCIPLE

A partner must add not status, but the capability to launch.

IDENTIFY — PACKAGE — INTEGRATE — SCALE

Dubai is entering its longevity era.

The creation of the Dubai Longevity Authority marks a strategic shift toward regulated longevity, wellness, advanced healthcare and sector investment flows. The UAE is not just our base — it is a catalyst for international growth.

01

Clinical base

solution piloting and data collection

02

Capital

investors and strategic partners

03

Regulation

IP, licensing and joint ventures

04

Global access

GCC, Asia, Europe and the CIS



Model42 is positioned as a private-sector growth platform aligned with this direction.

Four strategic pillars. One integrated platform.

One platform — not four separate companies.



AI Preventive Healthcare

Smart screening, health analytics and diagnostics access.



Longevity & Regenerative Medicine

Curated longevity protocols and selected advanced programs.



Medical Education & Accreditation

Doctor training, certification pathways and protocol adoption.




Premium Health Distribution

Corporate wellness, clinic networks, doctors and concierge access.

An operating machine, not a concept.

A disciplined, repeatable process — from validated solution to scalable market platform.



Corporates · Clinics · Doctors · Medical networks · Premium clients

Four operating levels. One targeted intelligent framework.

Each level creates its own value; their integration must generate a platform effect — the target architecture.

01

Diagnostics

structured data and risks

02

Therapy

protocols and personalized solutions

03

Education

professional training and unified standards

04

Scaling

partnerships, licensing and joint ventures

TARGET MODEL42 LOOP

Data → Knowledge → Expert decision → Application → Reassessment

The future analytical layer is a support tool for licensed professionals, not a replacement — used only with the required consents and under applicable law.

A portfolio with an operating logic.

Diagnostics generate data; therapy puts it into action; training makes it the standard. Status is stated separately for each.

ACTIVE

Portfolio & partnership solutions

- 01 Clinics On Cloud
- 02 ANF Therapy
- 03 ANF Academy
- 04 The Longevity Code
- 05 Energy Max Group (incl. Maxilin flagship technology)
- 06 New medical and biotech assets

UNDER DEVELOPMENT

Model42 infrastructure

- 01 Model42 Compounding Pharmacy
- 02 International joint ventures
- 03 Unified digital infrastructure

PORTFOLIO SOLUTION

Clinics On Cloud

Diagnostics become accessible wherever the patient is: modular point-of-care diagnostic infrastructure — the Model42 diagnostic layer.

12M+

tests conducted

based on company data

3,500+

diagnostic systems deployed

based on company data

ONE DIAGNOSTIC STANDARD

Collection → Analysis → Interpretation → Integration

Results are interpreted by licensed specialists and used to determine further medical actions.



Value is created by the professional protocol — and scaled by education.



PORTFOLIO SOLUTION

ANF Therapy · ANF Care

Assessment, personalized selection, application and professional monitoring. Application only by trained and, where required, licensed professionals.



ACTIVE PROGRAM

ANF Academy

Specialist training, clinic partnerships, standardized protocols and consistent quality standards across every new market.



ACTIVE PROGRAM

The Longevity Code

International educational program in functional, preventive and regenerative medicine. Knowledge · protocols · international exchange.

New infrastructure, and a strategic partner already at scale.



IN DEVELOPMENT

Model42 Compounding Pharmacy

Personalized prescription medications through a launch model based on a local license: a joint venture with a local partner, or licensing / franchising only where legally permissible and approved by the regulator.



ACTIVE PARTNERSHIP

Energy Max Group · Maxilin

Development and manufacturing of premium biotechnological products. Maxilin brings advanced microbiome solutions into Model42 B2B/B2C channels — exclusive of the MLM model. 30+ countries · 25% cross-ownership.

Backed by an investment platform and an international partner.



STRATEGIC PLATFORM

Enlightened Minds Investments

Provides the framework, capital access and execution support — and turns medical opportunities into structured investment platforms.

- 01 Corporate architecture — ownership and partnership structures
- 02 Capital access — investors and strategic relationships
- 03 New markets — international joint ventures and partners
- 04 Deals and execution — e.g. cross-ownership with Energy Max Group



STRATEGIC INTERNATIONAL PARTNER

NAZR Ventures

Healthcare · Life Sciences · Longevity · AI — deal sourcing, capital access, commercialization.

- 01 International investors and family investment offices
- 02 Medical and institutional organizations
- 03 Sourcing and selection of new technologies and companies
- 04 Market entry: North America, Europe, Asia and the Middle East

Technology becomes an investment asset — with a clear ownership structure and a growth roadmap.

- 01 Selection
- 02 Due diligence
- 03 Capital & rights
- 04 Implementation
- 05 Scale

Medical expertise · investment discipline · global execution

Three potential levels of value creation.

A successful launch in a new market can expand operations, contractual rights and the value of portfolio assets.

01

Operating revenue

Diagnostic systems and services · professional application · training · local pharmacy structures

02

Platform revenue

Licensing rights · viable franchise models · joint ventures

03

Portfolio value

Growth in value of verified stakes, rights, IP and infrastructure

STRATEGIC ASSETS — RECOGNIZED ONLY WITH SUPPORTING DOCUMENTATION

Equity interests

incl. a 25% stake in Energy Max Group

EXISTING / ACQUIRED

Commercial rights

solutions in agreed territories

CONTRACT-BASED ONLY

Operational infrastructure

training, partnerships, licensing, launch

UNDER DEVELOPMENT

Intellectual property

digital tools, expertise, scaling model

EXISTING / IN DEVELOPMENT

Priority markets are evaluated progressively, not simultaneously.

Entry model	Control	Capital	Speed
Direct presence	Maximum	High	Medium
Joint venture	Shared	Shared	Medium
Franchising	Contractual standards	Partner	Higher*
Licensing / distribution	Limited	Partner	High

* Only if permitted by the applicable jurisdiction.

01 **The UAE**
base market and international hub

02 **GCC countries**
the regional growth wave

03 **CIS**
Russia, Kazakhstan, Uzbekistan and neighboring markets

04 **Selected international**
select markets in Asia, Europe and Africa

A single successfully launched market creates the operational model for the next wave.

Bring the capability to launch. We bring the platform.

A license, infrastructure, an audience, capital or a scientific base — the partnership format follows the market objective.

Clinics On Cloud

Diagnostic infrastructure
for clinics, corporations,
remote sites

ANF Therapy

Professional network,
training, application
standards

Model42 Compounding

Joint venture or a legally
compliant partnership

Education & science

Professional programs
and institutional
initiatives

Energy Max · Maxilin

Probiotic protocols in
clinical practice via direct
B2B

HOW WE START — SIX STAGES TURN INTEREST INTO A CONTROLLED LAUNCH

01

Meeting

objective and responsible
party

02

Market assessment

demand and economics

03

Solution selection

fit with market demands

04

Regulatory model

licenses and structure

05

Training & launch

team and operational plan

06


Scale

metrics and scaling conditions

Every launch must have an owner, a licensing framework and a measurable outcome.

Founded inside clinical practice, not around it.

Strategic management, medical expertise and international development.



EXECUTIVE CHAIR

Timur Kudratov

Strategic Planning, Capital & Ecosystem
Architecture



VICE CHAIR

Dr. Raees Tonse, MD, MBA


Oncology, Precision Medicine & International
Partnerships



MANAGING PARTNER

Dr. Aida Gadjeva

Medical Products & Innovation



INVESTOR RELATIONS LEADER

Leyla Didigova

Head of Investor Relations at Model42

International Advisory Board

Institutional strategy, investment management, healthcare financing, sustainability and new markets.



Ali Qassim Al-Asiri

Strategy & Public Sector
Transformation



**Mohammed Alkaff
Al-Hashmi**

Finance, Technology &
Strategic Investments



Carlo Almeida

Latin America: Business &
Partnership Development



**Dr. Samiullah
(Samuel) Khan**

ESG, Net Zero & Sustainable
Transformation




Armands Murnieks

Nutraceuticals,
International
Commercialization



Dr. Dennis Sebastian

Health Insurance &
Healthcare Financing



Chad Chavanda

Africa: Market Development
& International Trade

BY INVITATION

Private Investor Dinner

The evening format Model42 holds with prospective investors: the platform, the portfolio and the people behind it — around one table.

FOR INVESTORS & FAMILY OFFICES

Investor application

Platform and portfolio-level discussion, structured information access, investor relations as one point of contact.

[Apply online →](#)

FOR CLINICS, DOCTORS, DISTRIBUTORS

Partner application

Five partnership formats; a launch with an owner, a licensing framework and success criteria.

[Apply online →](#)

Important information

This document is intended solely for preliminary review and discussion purposes.

01

Document status

For informational and marketing purposes only. It does not constitute a public offer, investment recommendation, or medical or legal advice.

02

Plans and forecasts

Information on plans, markets, potential revenues and asset values contains forward-looking statements and does not guarantee future results. Recipients should conduct their own due diligence.

03

Medical & pharmaceutical

Model42 does not independently provide medical or pharmaceutical services. Such services are provided only by separately licensed entities and professionals.

04

Technology, data and AI

Describing a technology does not imply confirmed efficacy, safety or regulatory approval in any market. Data and AI tools are used only with the necessary consents and under applicable law.

Any cooperation is governed exclusively by signed agreements and applicable law.

Shaping the future of health and longevity together

model42.ae

info@model42.ae

ICTS Training Center · 25A St, Al Quoz Industrial Area 3 · Dubai, UAE

POWERED BY

